CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer

American Journal of Surgery

Volumn 172, Issue 4, 1996, Pages 350-352

  Willett, Christopher G ^a,b   Daly, William J ^a   Warshaw, Andrew L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; FLUOROURACIL;

ANTIGEN DETECTION; ARTICLE; BIOLOGICAL MONITORING; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; HUMAN; METASTASIS; PANCREAS CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030273040     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(97)89547-5     Document Type: Article

References (6)

1. 1. Warshaw AL, Fernandez-Del Castillo C. Pancreatic carcinoma. NEJM. 1992;326:455-464.
2. 2. Beretta E, Malesci A, Zerbi A, et al. Serum CA 19-9 in the postsurgical follow-up of patients with pancreatic cancer. Cancer. 1987;60:2428-2431.
3. 3. Glenn J, Steinherg WM, Kurtzman SH, et al. Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol. 1988;6:462-468.
4. 4. Willett CG, Lewandrowski K, Warshaw AL, et al. Resection margins in carcinoma of the head of the pancreas. Ann Surg. 1993;217:144-148.
5. 5. Shipley WU, Wood WC, Tepper JE, et al. Intraoperative electron beam irradiation for patients with unresectable pancreatic carcinoma. Ann Surg. 1984;200:289-296.
6. 6. Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumor marker CA 19-9 in acute cholangitis. Dig Dis Sci. 1988;33:1223-1225.